Literature DB >> 19492157

Prolactin does not affect human platelet aggregation or secretion.

Anne Q Reuwer1, Rienk Nieuwland, Isabelle Fernandez, Vincent Goffin, Claudia M van Tiel, Marianne C L Schaap, René J Berckmans, John J P Kastelein, Marcel Th B Twickler.   

Abstract

Platelets play an important role in the development of plaque formation and in the events after rupture of the atherosclerotic plaque, leading to atherothrombosis. Multiple hormones, either in excess or when deficient, are involved in the development of atherothrombotic disease, but, to which extent such hormones affect platelet function, is still controversial. It was the objective of this study to assess the ability of the pituitary hormone prolactin to affect platelet functions. Venous blood was collected from six healthy males. Platelet activation was studied by (i) flow cytometry in whole blood (exposure of P-selectin as a measure of platelet secretion, and binding of PAC-1 as a measure of ligand-binding conformation of alpha(IIb)beta(3)), and by (ii) optical aggregation and whole blood aggregation. All studies were performed without and with exposure to several concentrations of ADP (0.1, 0.5 and 1.0 microM) and prolactin (50 and 1,000 microg/l). The presence of the prolactin receptor was investigated by Western blot and flow cytometry. In response to either 50 or 1,000 microg/l prolactin, no evidence of platelet activation or aggregation was found. In addition, ADP-induced platelet activation or aggregation was not enhanced by prolactin. Finally, prolactin receptors could not be detected on the surface of platelets. The present data indicate that prolactin does not directly modulate platelet function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19492157

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

Review 1.  The treatment of hyperprolactinemia in postmenopausal women with prolactin-secreting microadenomas: cons.

Authors:  Alexander T Faje; Anne Klibanski
Journal:  Endocrine       Date:  2014-06-03       Impact factor: 3.633

2.  Exocytosis Protein DOC2B as a Biomarker of Type 1 Diabetes.

Authors:  Arianne Aslamy; Eunjin Oh; Miwon Ahn; Abu Saleh Md Moin; Mariann Chang; Molly Duncan; Jeannette Hacker-Stratton; Mohamed El-Shahawy; Fouad Kandeel; Linda A DiMeglio; Debbie C Thurmond
Journal:  J Clin Endocrinol Metab       Date:  2018-05-01       Impact factor: 5.958

3.  Macroprolactinemia, like hyperprolactinemia, may promote platelet activation.

Authors:  Inan Anaforoglu; Melek Eda Ertorer; Ilknur Kozanoglu; Birsel Unal; Filiz Eksi Haydardedeoglu; Okan Bakiner; Emre Bozkirli; Neslihan Bascil Tutuncu; Nilgun Guvener Demirag
Journal:  Endocrine       Date:  2010-02-03       Impact factor: 3.633

4.  Prolactin may not play a role in primary antiphospholipid (Hughes') syndrome.

Authors:  Manoel Tavares Neves Junior; Carlos Ewerton Maia Rodrigues; Jozelio Freire de Carvalho
Journal:  Clin Dev Immunol       Date:  2011-04-07

5.  Risk of thromboembolic events in patients with prolactinomas compared with patients with nonfunctional pituitary adenomas.

Authors:  Sann Yu Mon; Abdulrahman Alkabbani; Amir Hamrahian; Julie N Thorton; Lawrence Kennedy; Robert Weil; Leann Olansky; Krupa Doshi; Vinne Makin; Betul Hatipoglu
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

Review 6.  Drug-induced thrombosis: an update.

Authors:  Yuval Ramot; Abraham Nyska; Galia Spectre
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

7.  Platelet Function in CKD: A Systematic Review and Meta-Analysis.

Authors:  Constance C F M J Baaten; Marieke Sternkopf; Tobias Henning; Nikolaus Marx; Joachim Jankowski; Heidi Noels
Journal:  J Am Soc Nephrol       Date:  2021-05-03       Impact factor: 14.978

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.